Tweets
High mortality risk predictors in patients with anti-MDA5 dermatomyositis include:
- rapidly progressive interstitial lung disease
- anti-Ro52 antibody
- age > 57 years
(based on study of 126 MDA-5+ DM pts)
https://t.co/VCyLhStFgX https://t.co/y3CyzOlwDt
Links:
Dr. John Cush @RheumNow ( View Tweet )
2 years 7 months ago
Spanish study of 518 #SLE patients, 7% of whom received at least one dose of rituximab(26) or belimumab (11). RTX given for either hemolytic anemia or ITP (11 pts), nephritis & CNS SLE (5 pts ea). BEL mostlyfor arthritis (8 pts) https://t.co/IqCVfOL5rb https://t.co/ocLj7Ejs7A
Links:
Dr. John Cush @RheumNow ( View Tweet )
2 years 7 months ago
Study of Veterans, Medicare, Medicaid RA pts (73070) pts, matched 1:10 w/ non-RA (639268) looked ataortic valve risk; RA pts have incr risk incident AS (adj HR 1.48), aortic valve surgery (aHR 1.34) & AS-related death (aHR 1.26). AS incidence=3.97/1000PYs https://t.co/rvA59hn6FE https://t.co/IS9jjuhYWv
Links:
Dr. John Cush @RheumNow ( View Tweet )
2 years 7 months ago
Synovial T cells from 20 pts Rx w/ immune checkpoint inhibitors who developed ICI-arthritis compared w/ synovial T cells from RA & PsA pts - showing clonal expansion of activated effector CD38hi,CD127−, CD8 T cells, w/ incr type I IFN-assoc transcripts https://t.co/vw2sOGL6jQ https://t.co/uDlt9dH4mQ
Links:
Dr. John Cush @RheumNow ( View Tweet )
2 years 7 months ago
Metabolic Burden in the Early Stages of PsA
Dr. Aurelie Najm discusses abstract OP0066 presented at EULAR 2023 in Milan, Italy.
https://t.co/08qOjVJE9A https://t.co/eH6oWsB1dT
Links:
Dr. John Cush @RheumNow ( View Tweet )
2 years 7 months ago
The Importance of Knowing Which Entheses are Involved in PsA
Dr. Eric Ruderman discusses abstract POS0027 presented at EULAR 2023 in Milan, Italy.
https://t.co/nRJfNxwDF0 https://t.co/LUgLQTIUDD
Links:
Dr. John Cush @RheumNow ( View Tweet )
2 years 7 months ago
New Full Length from A&R:
A Double-Blind, Randomized, Placebo-Controlled, Phase 2 Trial of Obexelimab in Systemic Lupus Erythematosus with Exploration of Response Based on Gene Pathway Co-Expression Patterns
https://t.co/5pzBfiZaNt
Created with https://t.co/L5O6lHuNSY https://t.co/HvDy4b1Bg3
Links:
ACR_Journals @ACR_Journals ( View Tweet )
2 years 7 months ago
Retrospective study of 1877
pts. W/ granulomatosis with polyangiitis (GPA) on RTX found only 23% received TMP-SMX for a median of 141 days. Prophylaxis was assoc w/ prednisone use (OR 3.96), MTX use (OR 1.48), ICU care (OR 1.95), hospitalization(OR 1.56) https://t.co/JRUC8HUwJU
Links:
Dr. John Cush @RheumNow ( View Tweet )
2 years 7 months ago
Pain in the Neck
https://t.co/JxNBJvlekM https://t.co/vaPSDK2vHQ
Links:
Dr. John Cush @RheumNow ( View Tweet )
2 years 7 months ago
IL-23 Inhibitor Performance in Psoriatic Disease
A single center real-world observational study shows three commercially available IL-23 inhibitors have high and similar drug survival and effectiveness in difficult-to-treat psoriasis and PsA.
https://t.co/J3HIDBguj1 https://t.co/uqYf0Bdh0n
Links:
Dr. John Cush @RheumNow ( View Tweet )
2 years 7 months ago
2023 ACR/EULAR Criteria for Calcium Pyrophosphate Deposition Disease
The prevalence of radiographic chondrocalcinosis is estimated to be 4% to ≥10% in older adults, but the prevalence of symptomatic CPPD disease is unknown.
https://t.co/yNQkEwRT3W https://t.co/YG7uBpDrPP
Links:
Dr. John Cush @RheumNow ( View Tweet )
2 years 7 months ago
SGLT2 inhibitor (empagliflozin) given in a lupus mouse (MRL/lpr) model showed a renoprotective effect suggesting the value of non-immunosuppressive therapies to improve renal function. Showed less -dsDNA Abs, proteinuria, renal nephritis damage https://t.co/iPhecsJeJX https://t.co/0TIy2hsPC1
Links:
Dr. John Cush @RheumNow ( View Tweet )
2 years 7 months ago
